- 2600 Stemmons Freeway,
- Suite 176
- Dallas, TX 75207-2107
- Tel: (214) 905-5100
- Fax: (214) 905-5101
Oral mucositis is a frequent complication of cancer chemotherapy or of radiation therapy to the head and neck region. Currently available products are usually inadequate, and more effective treatment to minimize the extent and duration of mucositis is clearly needed. Historically, treatment of mucositis has been palliative and aimed at minimizing mucosal trauma. Treatments include frequent mouth cleansing and rinsing with buffered saline and fluoride solutions and administration of topical and systemic antimicrobial agents. Mucositis and infection of the mouth have remained major complications despite the usual oral care provided for patients with cancer.
MuGard is a viscous, mucoadhesive rinse which provides a protective coating to the oral mucosa. In a comparison of patients undergoing standard care with patients using MuGard, the incidence and severity of mucositis was significantly lower for the MuGard group. MuGard has received marketing allowance in the United States under a 510(k) from the Food and Drug Administration.
Access has conducted a clinical trial of MuGard, the results of which were compared to historical data from two different sources for patients at risk of developing mucositis and who had received prior standard of care treatment. (Cancer; 1999, 85 (10): 2103-2113, and Cancer; 2000, 89 (11): 2258-2265). In both cases, it was shown mucositis scores, as measured by the oral mucositis assessment scale (OMAS), were lower for patients using MuGard than for similar patients on standard care. For more information, visit www.MuGard.com